Topic:

Partnering

Latest Headlines

Latest Headlines

Actavis picks Particle Sciences for generics development

Contract developer Particle Sciences has nailed down a deal with Actavis, lending its drug delivery expertise to the generics giant. 

WuXi bets on anti-counterfeiting tech with an eye on drug safety

WuXi PharmaTech, China's largest pharma outsourcing outfit, is investing in a startup that makes tiny, edible bar codes designed to prevent drug counterfeiting, planning to offer the same technology to its manufacturing customers.

Clinipace signs up to get a brain-stimulating device on the U.S. market

Global CRO Clinipace has agreed to manage clinical trials for Nexstim as the Finnish devicemaker works toward FDA approval for its neurostimulation therapy.

Merck and Ferring team up on anti-bleeding drug for the developing world

Alongside Swiss drugmaker Ferring and the World Health Organization, Merck is embarking on a multinational effort to develop an easily transportable treatment for excessive bleeding, hoping to curb global rates of postpartum hemorrhage among the world's poorest mothers.

Foundation Medicine will develop a test for Clovis' ovarian cancer drug

Foundation Medicine will develop a companion diagnostic test for use with a Clovis Oncology drug now in mid-stage clinical trials to treat patients with ovarian cancer.

Battered Amarin finally lands a partner for Vascepa

After a rough go with the FDA sent its shares spiraling downward, Amarin has at last found a partner to help commercialize its fish-oil-derived pill for high triglycerides.

Merck KGaA teams up with Pfizer to spotlight new lupus therapies

Rival drugmakers Merck KGaA and Pfizer are putting their cash and expertise into a new effort to better understand lupus, tapping the Broad Institute for a Big Data approach to help map out the disease and light the way for future drug candidates.

Celgene doubles down on Forma with a $600M discovery deal tied to a buyout option

Close to a year after Forma Therapeutics' executive team hammered out a partnership with Celgene packed with $200 million in early-stage payouts, the big biotech outfit has come back with a $600 million discovery deal that might eventually lead the pair to the M&A altar.

AstraZeneca cozies up to MRC scientists amid an R&D rethink

AstraZeneca isn't due to move into its new Cambridge, U.K., headquarters for another two years, but the British giant is already laying the groundwork for open collaboration in the biomedical hub, signing a deep-seated deal with the government-run Medical Research Council to work on drug discovery.

BioClinica bags $30M in Big Pharma deals

CRO BioClinica said it inked two long-term deals with major drugmakers totaling $30 million, touting its eClinical technology as driving sponsor interest.